Novel application and serial evaluation of tissue-engineered portal vein grafts in a murine model

Mark W., Maxfield, Mitchel R., Stacy, Hirotsugu, Kurobe, Shuhei, Tara, Tai, Yi, Muriel A., Cleary, Zhen W., Zhuang, Manuel I., Rodriguez-Davalos, Sukru H., Emre, Yasuko, Iwakiri, Toshiharu, Shinoka, Christopher K., Breuer

Regenerative Medicine |

Aim: Surgical management of pediatric extrahepatic portal vein obstruction requires meso-Rex bypass using autologous or synthetic grafts. Tissue-engineered vascular grafts (TEVGs) provide an alternative, but no validated animal models using portal TEVGs exist. Herein, we preclinically assess TEVGs as portal vein bypass grafts. Materials & methods: TEVGs were implanted as portal vein interposition conduits in SCID-beige mice, monitored by ultrasound and micro-computed tomography, and histologically assessed postmortem at 12 months. Results: TEVGs remained patent for 12 months. Histologic analysis demonstratedformationofneovesselsthatresemblednativeportalveins,withsimilarcontentofsmoothmuscle cells, collagen type III and elastin. Conclusion: TEVGs are feasible portal vein conduits in a murine model. Further preclinical evaluation of TEVGs may facilitate pediatric clinical translation.